Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.647,44
0,25%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Leap Therapeutics Inc (LPTX) Leap Therapeutics Inc (LPTX) Notizie

LPTX

Leap Therapeutics (LPTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LPTX
DataOraFonteTitoloSimboloCompagnia
24/05/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:LPTXLeap Therapeutics Inc
23/05/202422:25Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:LPTXLeap Therapeutics Inc
13/05/202413:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPTXLeap Therapeutics Inc
13/05/202413:00PR Newswire (US)Leap Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
13/05/202412:50Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPTXLeap Therapeutics Inc
10/05/202423:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LPTXLeap Therapeutics Inc
11/04/202414:30PR Newswire (US)Leap Therapeutics Announces $40 Million Private PlacementNASDAQ:LPTXLeap Therapeutics Inc
18/03/202412:00PR Newswire (US)Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
01/02/202403:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPTXLeap Therapeutics Inc
26/01/202423:21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LPTXLeap Therapeutics Inc
16/01/202423:05PR Newswire (US)Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers SymposiumNASDAQ:LPTXLeap Therapeutics Inc
03/01/202413:00PR Newswire (US)Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LPTXLeap Therapeutics Inc
02/01/202413:00PR Newswire (US)Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer PatientsNASDAQ:LPTXLeap Therapeutics Inc
11/12/202322:05PR Newswire (US)Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers SymposiumNASDAQ:LPTXLeap Therapeutics Inc
21/11/202313:00PR Newswire (US)Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:LPTXLeap Therapeutics Inc
13/11/202313:00PR Newswire (US)Leap Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
05/09/202313:00PR Newswire (US)Leap Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:LPTXLeap Therapeutics Inc
14/08/202313:00PR Newswire (US)Leap Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
12/07/202313:00PR Newswire (US)Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer PatientsNASDAQ:LPTXLeap Therapeutics Inc
20/06/202318:30PR Newswire (US)Leap Therapeutics Announces Reverse Stock SplitNASDAQ:LPTXLeap Therapeutics Inc
15/06/202312:26Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:LPTXLeap Therapeutics Inc
14/06/202322:32Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:LPTXLeap Therapeutics Inc
09/06/202322:11Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:LPTXLeap Therapeutics Inc
25/05/202323:19Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LPTXLeap Therapeutics Inc
25/05/202323:10PR Newswire (US)Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual MeetingNASDAQ:LPTXLeap Therapeutics Inc
15/05/202313:07Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LPTXLeap Therapeutics Inc
15/05/202313:00PR Newswire (US)Leap Therapeutics Reports First Quarter 2023 Financial ResultsNASDAQ:LPTXLeap Therapeutics Inc
28/04/202322:23Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:LPTXLeap Therapeutics Inc
28/04/202322:21Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:LPTXLeap Therapeutics Inc
21/04/202323:13Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:LPTXLeap Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LPTX

La tua Cronologia

BOV
BHEW39
BlackRock Institutional ...
BOV
ITUBS341
ITUBS341 Ex:32,72
ASX
LLCKOQ
TSX
HXF
Global X S&P TSX Capped ...
BIT
UB9P79
Unicredit Bank
AMEX
IQSI
IQ Candriam Internationa...
COIN
EXBBTC
COIN
BWKUSD
LSE
PIA
Pilat
BIT
F15783
Vontobel Financial Produ...
LSE
BRTG
Ubs Etc Brent G
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network